Liraglutide is an acylated GLP-1 agonist indicated for the treatment of diabetes mellitus and as an adjunct to diet regulation and physical exercise for the management of chronic obesity in adults with a BMI ≥30 kg/m2 (Cena et al. 2020). The gene discussed is GLP1R; the disease is diabetes mellitus.